PHARMACOKINETICS OF CINOXACIN IN PATIENTS WITH IMPAIRED RENAL FUNCTION
The pharmacokinetics of cinoxacin, a new synthetic antibacterial agent, were examined in 6 healthy volunteers and 12 patients with different endogeneous creatinine clearances (Ccr) on the basis of a one-compartment open model. Each subject received a single 400mg oral dose of cinoxacin, and serum an...
Saved in:
| Published in | CHEMOTHERAPY Vol. 28; no. Supplement4; pp. 133 - 138 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
Japanese Society of Chemotherapy
01.01.1980
|
| Online Access | Get full text |
| ISSN | 0009-3165 1884-5894 |
| DOI | 10.11250/chemotherapy1953.28.Supplement4_133 |
Cover
Loading…
| Abstract | The pharmacokinetics of cinoxacin, a new synthetic antibacterial agent, were examined in 6 healthy volunteers and 12 patients with different endogeneous creatinine clearances (Ccr) on the basis of a one-compartment open model. Each subject received a single 400mg oral dose of cinoxacin, and serum and urinary concentrations of free cinoxacin and cinoxacin conjugate were measured by a fluorometric method. The mean peak concentration of free cinoxacin in serum was achieved 3 hours after administration in normal subjects. The mean serum half-life of free cinoxacin was calculated for 66 minutes in normal subjects, and increased in patients along with increasing impairment of renal function. A significant correlation between the elimination rate constant and Ccr was demonstrated (p<0.001). In normal subjects, 62% of the drug was excreted in the urine as free cinoxacin within the first 12 hours, 95% as total cinoxacin including cinoxacin conjugate. The urinary excretion rate declined gradually in patients as a degree of renal impairment advanced. |
|---|---|
| AbstractList | The pharmacokinetics of cinoxacin, a new synthetic antibacterial agent, were examined in 6 healthy volunteers and 12 patients with different endogeneous creatinine clearances (Ccr) on the basis of a one-compartment open model. Each subject received a single 400mg oral dose of cinoxacin, and serum and urinary concentrations of free cinoxacin and cinoxacin conjugate were measured by a fluorometric method. The mean peak concentration of free cinoxacin in serum was achieved 3 hours after administration in normal subjects. The mean serum half-life of free cinoxacin was calculated for 66 minutes in normal subjects, and increased in patients along with increasing impairment of renal function. A significant correlation between the elimination rate constant and Ccr was demonstrated (p<0.001). In normal subjects, 62% of the drug was excreted in the urine as free cinoxacin within the first 12 hours, 95% as total cinoxacin including cinoxacin conjugate. The urinary excretion rate declined gradually in patients as a degree of renal impairment advanced. |
| Author | KAWAGUCHI, KOHEI KURODA, KYOICHI OKASHO, AKIRA OHKAWA, MITSUO SUGATA, TOSHIAKI TAKANO, MANABU SAWAKI, MASARU |
| Author_xml | – sequence: 1 fullname: OHKAWA, MITSUO organization: Department of Urology, School of Medicine, Kanazawa University – sequence: 1 fullname: SUGATA, TOSHIAKI organization: Department of Urology, School of Medicine, Kanazawa University – sequence: 1 fullname: KURODA, KYOICHI organization: Department of Urology, School of Medicine, Kanazawa University – sequence: 1 fullname: OKASHO, AKIRA organization: Department of Urology, School of Medicine, Kanazawa University – sequence: 1 fullname: SAWAKI, MASARU organization: Department of Urology, School of Medicine, Kanazawa University – sequence: 1 fullname: KAWAGUCHI, KOHEI organization: Department of Urology, School of Medicine, Kanazawa University – sequence: 1 fullname: TAKANO, MANABU organization: Department of Urology, School of Medicine, Kanazawa University |
| BookMark | eNpdkM1OwkAcxDcGExF5h30Ai_vfj3Z73NRWNkJLoERv67ZsBQKlaeuBt5dED4RkMpM5zBx-j2hQn2qH0DOQCQAV5KXcuuOp37rWNmcIBZtQOVn9NM3BHV3dcwOM3aEhSMk9IUM-QENCSOgx8MUDGnfdriAEgPhU0iFKFlO1nKsoe9dpnOtohbMERzrNPtXF8UULles4zVf4Q-dTrOcLpZfxK17GqZrhZJ1Guc7SJ3Rf2UPnxv85QuskzqOpN8vedKRm3p4y6D2wVUmpY6UMfbIhBeM03NCCAq84p74vSt9VDixnUkBhiZVW2CDkZRCArGzARujr73ff9fbbmabdHW17Nrbtd-XBmVs2hkpzzeamXlBdTW1rXM1-AXVUaeE |
| ContentType | Journal Article |
| Copyright | Japanese Society of Chemotherapy |
| Copyright_xml | – notice: Japanese Society of Chemotherapy |
| DOI | 10.11250/chemotherapy1953.28.Supplement4_133 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1884-5894 |
| EndPage | 138 |
| ExternalDocumentID | article_chemotherapy1953_28_Supplement4_28_Supplement4_133_article_char_en |
| GroupedDBID | 53G ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL DIK JSF JSH KQ8 RJT RZJ ZOHVM |
| ID | FETCH-LOGICAL-j231t-1afc22e3c8960d0b3429d2b214f442665c6efe1a43851ba0a8a5a794c7718fa73 |
| ISSN | 0009-3165 |
| IngestDate | Wed Sep 03 06:29:47 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | Supplement4 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j231t-1afc22e3c8960d0b3429d2b214f442665c6efe1a43851ba0a8a5a794c7718fa73 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/chemotherapy1953/28/Supplement4/28_Supplement4_133/_article/-char/en |
| PageCount | 6 |
| ParticipantIDs | jstage_primary_article_chemotherapy1953_28_Supplement4_28_Supplement4_133_article_char_en |
| PublicationCentury | 1900 |
| PublicationDate | 1980-01-01 |
| PublicationDateYYYYMMDD | 1980-01-01 |
| PublicationDate_xml | – month: 01 year: 1980 text: 1980-01-01 day: 01 |
| PublicationDecade | 1980 |
| PublicationTitle | CHEMOTHERAPY |
| PublicationTitleAlternate | Chemother. |
| PublicationYear | 1980 |
| Publisher | Japanese Society of Chemotherapy |
| Publisher_xml | – name: Japanese Society of Chemotherapy |
| References | 6) SZWED, J. J.; D. E. BRANNON, R. S. SLOAN & F. C. LUFT: Pharmacokinetics of cinoxacin in patients with renal failure. J. Antimicrob. Chemother. 4: 451-454, 1978 4) ISRAEL, K. S.; H. R. BLACK, R. L. NELSON, M. K. BRUNSON, J. F. NASH, G. L. BRIER & J. D. WOLNEY: Cinoxacin: Pharmacokinetics and the effect of probenecid. J. Clin. Pharmacol. 18: 491-499, 1978 10) BRICKER, N. S.; P. A. F. MORRIN & S. W. KIME, Jr.: The pathologic physiology of chronic BRIGHT'S disease. Am. J. Med. 28: 77-98, 1960 5) RODRIGUEZ, N.; P. O. MADSEN & P. G. WELLING: Influence of probenecid on serum levels and urinary excretion of cinoxacin. Antimicr. Agents & Chemoth. 15: 465-469, 1979 1) 大越正秋: 第26回日本化学療法学会東日本支部総会, 新薬シンポジウム, Cinoxacin, 東京, 1979 3) BURT, R. A. P.; T. MORGAN, J. PAYNE & R. M. BENNER: Cinoxacin concentrations in plasma, urine and prostatic tissue after oral administration to man. Br. J. Urol. 49: 147-152, 1977 7) BLACK, H. R.; K. S. ISRAEL, R. L. WOLEN, G. L. BRIER, B. D. OBERMEYER, E. A. ZIEGE & J. D. WOLNY: Pharmacology of cinoxacin in humans. Antimicr. Agents & Chemoth. 15: 165-170, 1979 8) DETTLI, L.; P. SPRING & S. RYTER: Multiple dose kinetics and drug dosage in patients with kidney disease. Acta. Pharmacol. Toxicol. 29 (Suppl): 211-224, 1970 2) ANDERSSON, K. E.; S. COLLEN & P. A. M ARDH: Studies on cinoxacin. 2. Assay of cinoxacin in body fluids and tissues. J. Antimicrob. Chemother. 3: 417-422, 1977 9) DETTLI, L.: Elimination kinetics and drug dosage in renal insufficiency patients. Triangle 14: 117-123, 1975 |
| References_xml | – reference: 3) BURT, R. A. P.; T. MORGAN, J. PAYNE & R. M. BENNER: Cinoxacin concentrations in plasma, urine and prostatic tissue after oral administration to man. Br. J. Urol. 49: 147-152, 1977 – reference: 7) BLACK, H. R.; K. S. ISRAEL, R. L. WOLEN, G. L. BRIER, B. D. OBERMEYER, E. A. ZIEGE & J. D. WOLNY: Pharmacology of cinoxacin in humans. Antimicr. Agents & Chemoth. 15: 165-170, 1979 – reference: 8) DETTLI, L.; P. SPRING & S. RYTER: Multiple dose kinetics and drug dosage in patients with kidney disease. Acta. Pharmacol. Toxicol. 29 (Suppl): 211-224, 1970 – reference: 4) ISRAEL, K. S.; H. R. BLACK, R. L. NELSON, M. K. BRUNSON, J. F. NASH, G. L. BRIER & J. D. WOLNEY: Cinoxacin: Pharmacokinetics and the effect of probenecid. J. Clin. Pharmacol. 18: 491-499, 1978 – reference: 5) RODRIGUEZ, N.; P. O. MADSEN & P. G. WELLING: Influence of probenecid on serum levels and urinary excretion of cinoxacin. Antimicr. Agents & Chemoth. 15: 465-469, 1979 – reference: 2) ANDERSSON, K. E.; S. COLLEN & P. A. M ARDH: Studies on cinoxacin. 2. Assay of cinoxacin in body fluids and tissues. J. Antimicrob. Chemother. 3: 417-422, 1977 – reference: 1) 大越正秋: 第26回日本化学療法学会東日本支部総会, 新薬シンポジウム, Cinoxacin, 東京, 1979 – reference: 6) SZWED, J. J.; D. E. BRANNON, R. S. SLOAN & F. C. LUFT: Pharmacokinetics of cinoxacin in patients with renal failure. J. Antimicrob. Chemother. 4: 451-454, 1978 – reference: 9) DETTLI, L.: Elimination kinetics and drug dosage in renal insufficiency patients. Triangle 14: 117-123, 1975 – reference: 10) BRICKER, N. S.; P. A. F. MORRIN & S. W. KIME, Jr.: The pathologic physiology of chronic BRIGHT'S disease. Am. J. Med. 28: 77-98, 1960 |
| SSID | ssib001106282 ssj0000626693 ssib058492509 ssib005879733 ssib008506721 |
| Score | 1.2227648 |
| Snippet | The pharmacokinetics of cinoxacin, a new synthetic antibacterial agent, were examined in 6 healthy volunteers and 12 patients with different endogeneous... |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 133 |
| Title | PHARMACOKINETICS OF CINOXACIN IN PATIENTS WITH IMPAIRED RENAL FUNCTION |
| URI | https://www.jstage.jst.go.jp/article/chemotherapy1953/28/Supplement4/28_Supplement4_133/_article/-char/en |
| Volume | 28 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | CHEMOTHERAPY, 1980/08/25, Vol.28(Supplement4), pp.133-138 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3BjtMwELXKIiEuKxAgYAHlwK2kJE6a2Ecrm5Js1LqkieieIieND5VY0Kp7gJ_klxg7jZstHBYEUmS1jjzqdCbjN5PxDEJvcUMaEUrfdhp4yMFK-jYltWPXgfBrRzbUE-pw8nwRJKV_sZ6uR6Mfg6ylm109ab7_9lzJ30gV5kCu6pTsH0jWEIUJ-AzyhREkDOOdZLxMWD5nEQcXPC7SSLchj9IFXzMYx3AtWZHGi2IFfnqRjNP5kqV5fD7OY5XvMysXkQlQ9cUKknjOiyTO2dJgXJ5k7BPTkdO0WJXcBGXKD6zQ8wVfJSnLTAA2K3N-ru9klzyNEnODZ2yVcG2PsjRnh5CDS4lzFHK4gG1ctcc0iaU6caT9vD8y9u2WvaVg5btuEJO2M7GE-PaUdK2NexuMyUDXdD9THRz1B6bV7Qpm7Hdpt6sJ8-sGAJAOxNYMfo56UTjBZDIgWxlit0pt7wVZHa-uMKmGq4--ArHqsFRcg2reQ_cx-C2ql0j2cfBa0lVHVgf10UhIwwHeVuUDB_XqABxS4IeaoCGsDgJqugOqf_YBetfz_f4OXAPQ2oLb0acsahRVPEKne_fHYh0fj9FoK56g2bEeW3xmGT224Or12FJ6bPV6bGk9tno9forKWVxEib3v72FvwavY2a6QDcat1xBwozdO7QE22uAau770FXCcNkErW1f4HrgFtXAEEVMB-0cTAqCSIvSeoZOrL1ftc2QpN1mSVhIcbnxv01KKa1lLT1KYI077Al12bFdfuyIu1b-T9cv_SPsMPTw8gK_Qye76pn0NKHhXv9Ga9RPhhqmi |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PHARMACOKINETICS+OF+CINOXACIN+IN+PATIENTS+WITH+IMPAIRED+RENAL+FUNCTION&rft.jtitle=CHEMOTHERAPY&rft.au=OHKAWA%2C+MITSUO&rft.au=SUGATA%2C+TOSHIAKI&rft.au=KURODA%2C+KYOICHI&rft.au=OKASHO%2C+AKIRA&rft.date=1980-01-01&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=0009-3165&rft.eissn=1884-5894&rft.volume=28&rft.issue=Supplement4&rft.spage=133&rft.epage=138&rft_id=info:doi/10.11250%2Fchemotherapy1953.28.Supplement4_133&rft.externalDocID=article_chemotherapy1953_28_Supplement4_28_Supplement4_133_article_char_en |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-3165&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-3165&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-3165&client=summon |